At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 130 enrolled
Drug / intervention
Olopatadine HCL Nasal Spray, 0.6% +1 moredrug
Likely dose
Fluticasone Propionate Nasal Spray, 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
In Brief
A Phase 4 clinical trial evaluating Olopatadine HCL Nasal Spray, 0.6% and Fluticasone Propionate Nasal Spray, 50 mcg for Seasonal Allergic Rhinitis. Completed, enrolled 130 participants across 1 site.
Detailed Summary
Comparison of two nasal sprays for the treatment of seasonal allergic rhinitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJun 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedJun 5, 2008
Enrollment StartMay 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.1 years ago
Interventions
Olopatadine HCL Nasal Spray, 0.6%drug
Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
Fluticasone Propionate Nasal Spray, 50 mcgdrug
Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily